Physician profile
Usama Mukayed
NPI 1861428260
$6,657.43
in general payments reported to CMS, 2019-2025
36 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $485 · 2021: $1,466 · 2022: $1,486 · 2023: $1,410 · 2024: $497 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201 · Education: $2.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.33 |
| Education | $2.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $816.47 | 2019-2025 | Triclip, Mitraclip, Aveir |
| Pfizer INC. | $638.51 | 2019-2024 | |
| Amgen INC. | $559.25 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $468.30 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $463.42 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $446.35 | 2019-2023 | Camzyos, Eliquis |
| Cardiovascular Systems INC. | $438.58 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $438.53 | 2019-2022 | |
| Endologix LLC | $408.38 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $333.95 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.31 | 2019-2024 | Jardiance |
| Boston Scientific Corporation | $160.74 | 2022-2024 | Watchman Access System, Bodyguardian |
| Sanofi-Aventis U.S. LLC | $145.00 | 2019-2022 | |
| Bolton Medical INC | $133.70 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.45 | 2019-2023 | Lifevest |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $110.46 | 2019-2023 | Kengreal |
| Esperion Therapeutics, INC. | $80.68 | 2021-2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $73.77 | 2024 | Arcalyst |
| Novo Nordisk INC | $70.05 | 2022-2024 | Ozempic, Rybelsus |
| Kestra Medical Technology Services, INC. | $64.58 | 2023 | Assure Wcd |
| Amarin Pharma, INC. | $61.58 | 2020-2021 | |
| Medtronic, INC. | $60.24 | 2023 | Cobalt Dr Mri Surescan |
| Abiomed | $48.70 | 2021-2023 | Impella |
| Arbor Pharmaceuticals, INC. | $46.91 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $44.15 | 2024-2025 | Onpattro |
| Vital Connect, INC | $40.91 | 2022 | |
| Portola Pharmaceuticals, LLC | $35.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.89 | 2023 | |
| Kiniksa Pharmaceuticals, Ltd. | $27.24 | 2022-2023 | Arcalyst |
| Astellas Pharma US INC | $22.13 | 2020 | |
| Glaxosmithkline, LLC. | $20.00 | 2025 | Shingrix, Arexvy |
| Philips North America LLC | $19.22 | 2025 | Extended Holter |
| Inogen, INC. | $17.66 | 2022 | |
| Bracco Diagnostics INC. | $15.77 | 2019 | |
| Gilead Sciences, INC. | $12.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usama Mukayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.